Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

Main Article Content

Andrew Blauvelt
Craig Leonardi
Claus Zachariae
Russel Burge
Terri Ridenour
Missy McKean-Matthews
Sandra Garces
Gregory Cameron


psoriasis, ixekizumab, clinical trial


Abstract Not Available

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>